A press release issued by Brigham and Women’s Hospital stated that a study done by physician-researchers from the International Mesothelioma Program at Brigham and Women’s Hospital, in collaboration with colleagues from Genentech, provides new genetic insights into diagnosing and treating patients with mesothelioma. Studies of other cancers have uncovered mutations which have allowed for a much more targeted approach to treatments. This recent study uncovered more than 2,500 alterations and 10 significantly mutated genes. These discoveries suggest that targeted therapies could be matched to an individual patient’s tumor. It is hopeful that these discoveries will aid in an accurate diagnosis of mesothelioma and predict which patients will have poor or better treatment outcomes. Right now, the five year survival rate for patients diagnosed with mesothelioma is between five and ten percent. This study hopes to find ways to raise that number and reduce the mortality rate of mesothelioma.